drugset

drugset / Trial / NCT00913874

To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fasting Conditions

NCT00913874 ↗

Phase 1 Completed 30 enrolled Sandoz

RandomizedCrossoverOpen-labelTreatment

Summary

To demonstrate the relative bioavailability of Divalproex Sodium 500 mg delayed release tablets under fasting conditions.

Timeline

Start: 2005-10
Primary completion: 2005-10
Completion: 2005-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Divalproex Sodium	Small molecule	500 mg	—

Indications